

Francesca Cottini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1761724/publications.pdf>

Version: 2024-02-01

55
papers

1,398
citations

471509

17
h-index

330143

37
g-index

56
all docs

56
docs citations

56
times ranked

2871
citing authors

#	ARTICLE	IF	CITATIONS
1	Redefining CD56 as a Biomarker and Therapeutic Target in Multiple Myeloma. <i>Molecular Cancer Research</i> , 2022, 20, 1083-1095.	3.4	8
2	Incidence, Treatment, and Survival of Patients With T-Cell Lymphoma, T-Cell Large Granular Leukemia, and Concomitant Plasma Cell Dyscrasias. <i>Frontiers in Oncology</i> , 2022, 12, 858426.	2.8	0
3	Improvement in Post-Autologous Stem Cell Transplant Survival of Multiple Myeloma Patients: A Long-Term Institutional Experience. <i>Cancers</i> , 2022, 14, 2277.	3.7	8
4	Functional expression of aryl hydrocarbon receptor as a potential novel therapeutic target in human multiple myeloma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2968-2980.	1.3	1
5	Interval Progression Serves As a Predictor of Adverse Outcomes in Patients with Multiple Myeloma. <i>Blood</i> , 2021, 138, 3940-3940.	1.4	0
6	Survival Analysis of Patients with T-Cell Lymphoma or T-Cell Large Granular Leukemia and Concomitant Plasma Cell Dyscrasias. <i>Blood</i> , 2021, 138, 2449-2449.	1.4	0
7	Targeting the Mitotic Checkpoint in Myeloma with OSU-13, a Novel Mps1/Ttk Inhibitor. <i>Blood</i> , 2021, 138, 2660-2660.	1.4	0
8	CD56 Has a Critical Role in Regulating Multiple Myeloma Cell Growth and Response to Therapies. <i>Blood</i> , 2021, 138, 889-889.	1.4	3
9	Early Versus Late Discontinuation of Maintenance Therapy in Multiple Myeloma. <i>Blood</i> , 2021, 138, 3796-3796.	1.4	1
10	Multiple Myeloma: Clinical Updates from the American Society of Clinical Oncology Annual Scientific Symposium 2020. <i>Journal of Clinical Medicine</i> , 2020, 9, 3626.	2.4	4
11	Real World Experience of Daratumumab: Evaluating Lymphopenia and Adverse Events in Multiple Myeloma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 575168.	2.8	8
12	Imaging intercellular interaction and extracellular vesicle exchange in a co-culture model of chronic lymphocytic leukemia and stromal cells by lattice light-sheet fluorescence microscopy. <i>Methods in Enzymology</i> , 2020, 645, 79-107.	1.0	6
13	Comparison of Patient Outcomes with Two Different Formulations of Melphalan As Conditioning Chemotherapy for Autologous Stem Cell Transplantation in Multiple Myeloma. <i>Blood</i> , 2020, 136, 1-1.	1.4	2
14	A novel APOA1 mutation in a patient with renal amyloidosis: unveiling amyloid by next-generation sequencing. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2019, 26, 253-254.	3.0	3
15	Characterization of Monoclonal Gammopathy of Undetermined Significance Progression to Multiple Myeloma through Meta-Analysis of GEO Data. <i>Blood</i> , 2019, 134, 4395-4395.	1.4	0
16	Daratumumab-Mediated Lymphocyte Kinetics Predict Adverse Events and Survival Outcomes in Patients with Multiple Myeloma. <i>Blood</i> , 2019, 134, 5501-5501.	1.4	0
17	Aryl Hydrocarbon Receptor (AHR) Antagonism As a Transformative, Dual-Mechanism Novel Therapy for Multiple Myeloma. <i>Blood</i> , 2018, 132, 1933-1933.	1.4	4
18	Meta-Analysis Illustrates Role of Interferon- β Signaling in Multiple Myeloma Pathogenesis. <i>Blood</i> , 2018, 132, 4510-4510.	1.4	0

#	ARTICLE	IF	CITATIONS
19	p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. <i>Blood</i> , 2017, 129, 1308-1319.	1.4	36
20	G-CSF improves safety when you start the day after autologous transplant in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2947-2951.	1.3	4
21	Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma. <i>Leukemia</i> , 2017, 31, 645-653.	7.2	47
22	Abstract PR13: p53-related protein kinase is a novel prognostic marker and therapeutic target in multiple myeloma. , 2017, , .		0
23	Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 13162-13167.	7.1	112
24	G-CSF Starting Day +1 after Autologous Transplant Is Safer Than Day +5 or Day +7 in Patients with Multiple Myeloma. <i>Blood</i> , 2016, 128, 5790-5790.	1.4	4
25	Combination of a Selective HSP90 α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. <i>PLoS ONE</i> , 2015, 10, e0143847.	2.5	20
26	Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma. <i>Leukemia</i> , 2015, 29, 1918-1927.	7.2	55
27	Anti-tumor activities of selective HSP90 α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma. <i>Leukemia</i> , 2015, 29, 510-514.	7.2	31
28	Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. <i>Cancer Discovery</i> , 2015, 5, 972-987.	9.4	97
29	Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma. <i>Blood Cancer Journal</i> , 2015, 5, e312-e312.	6.2	58
30	Abstract B09: Exploiting oncogene-induced DNA replicative stress as synthetic lethal approach to target myeloma.. , 2015, , .		0
31	Abstract PR04: Exploiting oncogene-induced DNA replicative stress as synthetic lethal approach to target myeloma.. , 2015, , .		0
32	Targeting Replicative Stress to Treat Hematological Disorders. <i>Blood</i> , 2015, 126, 2419-2419.	1.4	0
33	Novel therapeutic targets in multiple myeloma. <i>Clinical Advances in Hematology and Oncology</i> , 2015, 13, 236-48.	0.3	16
34	Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition. <i>Cancer Research</i> , 2014, 74, 4458-4469.	0.9	63
35	Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2489-2500.	4.1	23
36	Awakening the Hippo co-activator YAP1, a mercurial cancer gene, in hematologic cancers. <i>Molecular and Cellular Oncology</i> , 2014, 1, e970055.	0.7	9

#	ARTICLE	IF	CITATIONS
37	Genomics in Multiple Myeloma. , 2014, , 301-319.		2
38	Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. <i>Leukemia</i> , 2014, 28, 680-689.	7.2	128
39	Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. <i>Nature Medicine</i> , 2014, 20, 599-606.	30.7	250
40	Serine/Threonine Kinase STK4 Is a Novel Target in Myeloma. <i>Blood</i> , 2014, 124, 645-645.	1.4	23
41	Synthetic Lethal Approaches to Exploit Replicative Stress in Aggressive Myeloma. <i>Blood</i> , 2014, 124, 173-173.	1.4	0
42	Predictors of Biomarkers Guiding Targeted Therapeutic Strategies in Locally Advanced Lung Cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2013, 19, 263-271.	2.0	4
43	Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. <i>Leukemia</i> , 2013, 27, 2366-2375.	7.2	46
44	The Oncogene MYC Triggers Replicative Stress and DNA Damage In Multiple Myeloma. <i>Blood</i> , 2013, 122, 3114-3114.	1.4	0
45	Antitumor Activities Of An Oral Selective HSP90 α / β Inhibitor, TAS-116, In Combination With Bortezomib In Multiple Myeloma. <i>Blood</i> , 2013, 122, 4429-4429.	1.4	0
46	Targeting NAD ⁺ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. <i>Blood</i> , 2012, 120, 3519-3529.	1.4	133
47	Aberrant Non-Homologous End Joining in Multiple Myeloma: A Role in Genomic Instability and As Potential Prognostic Marker.. <i>Blood</i> , 2012, 120, 2932-2932.	1.4	3
48	TAS-117, a Novel Selective Akt Inhibitor Demonstrates Significant Growth Inhibition in Multiple Myeloma Cells in Vitro and in Vivo. <i>Blood</i> , 2012, 120, 942-942.	1.4	5
49	Rational Combination Treatment of a Novel Selective mTOR Kinase Inhibitor AZD8055 with IGF-1R Inhibitors in Multiple Myeloma. <i>Blood</i> , 2012, 120, 4023-4023.	1.4	0
50	The Role of the ABL1/YAP1/P73 Axis in Prevention of DNA Damage-Mediated Apoptosis in Multiple Myeloma. <i>Blood</i> , 2012, 120, 725-725.	1.4	0
51	General population low-count CLL-like MBL persists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. <i>Blood</i> , 2011, 118, 6618-6625.	1.4	131
52	Blockade of Nuclear Export Protein CRM1 (chromosomal region maintenance 1, XPO1) by a Novel, Potent and Selective CRM1 Inhibitor KPT-185 Induces Significant Antitumor Activity Against Human Multiple Myeloma. <i>Blood</i> , 2011, 118, 2913-2913.	1.4	2
53	Targeting NAD ⁺ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells. <i>Blood</i> , 2011, 118, 2920-2920.	1.4	0
54	Monoclonal B cell lymphocytosis in hepatitis C virus infected individuals. <i>Cytometry Part B - Clinical Cytometry</i> , 2010, 78B, S61-8.	1.5	43

#	ARTICLE	IF	CITATIONS
55	CLL-Like MBL In the General Population Persist Over Time, without Clinical Progression, Though Carrying the Same Cytogenetic Abnormalities of CLL. Blood, 2010, 116, 2440-2440.	1.4	1